Tag
This review synthesizes evidence linking aspirin use to reduced risk of calcific aortic valve disease in persons with elevated lipoprotein(a), highlighting the potential for targeted preventive strategies.
A novel deep learning algorithm accurately detects moderate or greater aortic stenosis using AI-guided focused cardiac ultrasound acquired by novice operators, presenting a scalable solution to expand screening accessibility.
In low-risk severe aortic stenosis patients, both TAVR and SAVR provide sustained health status improvements over seven years, with TAVR offering faster early recovery but similar long-term health outcomes.
In the EARLY TAVR registry, treadmill stress testing was safe and unmasked symptoms in 15% of asymptomatic severe aortic stenosis patients. Yet 20% of those with an indication for prompt aortic valve replacement remained untreated after one year.
The PARTNER 2A 10-year data show higher mortality and reintervention with balloon-expandable SAPIEN XT TAVR versus surgery in intermediate-risk patients, driven mainly by transthoracic access. Contemporary 10-year SAPIEN 3 data, however, su
The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in
A subgroup analysis of the DEDICATE-DZHK6 trial reveals that TAVI significantly reduces the 1-year risk of death or stroke compared to SAVR in both sexes, with particularly pronounced clinical benefits for women, especially regarding stroke
A large-scale multicenter study demonstrates that moderate mixed aortic valve disease (MAVD) carries a mortality risk comparable to severe aortic stenosis when symptoms or left ventricular dysfunction are present, challenging current guidel
A pivotal study using invasive exercise hemodynamics reveals that discordant low-gradient aortic stenosis behaves similarly to high-gradient severe disease, often masking underlying heart failure with preserved ejection fraction (HFpEF) phy
This review analyzes new registry data revealing that low discharge gradients (<10 mm Hg) after balloon-expandable ViV-TAVR correlate with reduced LVEF and higher 5-year mortality, challenging conventional hemodynamic success metrics.
Seven-year data from the PARTNER 3 trial demonstrate that TAVR remains noninferior to surgical aortic-valve replacement in low-risk patients, with comparable rates of death, stroke, and valve durability, supporting TAVR as a sustained alter
A substudy of the COMPARE-TAVI 1 trial identifies a unique NF-LEF phenotype in 10.7% of aortic stenosis patients. Despite reduced LVEF, these patients maintain normal flow through eccentric remodeling and achieve clinical improvements post-
The RHEIA trial substudy compares echocardiographic outcomes between TAVI and SAVR in women. While SAVR offers superior LVH regression and lower gradients, TAVI demonstrates significant benefits in preserving right ventricular function and
The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of
A life cycle assessment found SAVR produces roughly double the carbon footprint of transcatheter aortic valve replacement (TAVR), with postoperative ICU and ward care as the main drivers. Results highlight opportunities to decarbonize cardi
In a multinational registry of patients with concomitant aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR‑CA), both ATTR‑specific therapy (predominantly tafamidis) and aortic valve replacement (AVR) were independently associ
At 7 years, transcatheter and surgical aortic valve replacement show comparable outcomes including survival, stroke, and valve durability among low-risk patients with severe aortic stenosis, affirming TAVR’s long-term efficacy.
The COMPARE-TAVI 1 trial demonstrates non-inferiority of Myval transcatheter heart valves compared to SAPIEN 3 THVs at 1-year post-TAVI for a composite clinical endpoint in severe aortic stenosis patients.
The NOTION-2 trial demonstrates comparable three-year outcomes between TAVR and SAVR in low-risk patients aged 60-75 with severe tricuspid or bicuspid aortic stenosis, with low rates of valve deterioration and re-intervention.
A patient‑level meta‑analysis of randomized trials finds transcatheter aortic valve implantation (TAVI) reduces 1‑year risk of death or stroke versus surgical AVR in low– to intermediate‑risk patients—informing patient selection, heart‑team
